Dong Jiang

Array ( [id] => 20151568 [patent_doc_number] => 20250251406 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-08-07 [patent_title] => BIOMARKER-BASED TREATMENT AND DIAGNOSTIC METHODS FOR IL-17-DEPENDENT CONDITIONS [patent_app_type] => utility [patent_app_number] => 19/187615 [patent_app_country] => US [patent_app_date] => 2025-04-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16992 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19187615 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20321433 [patent_doc_number] => 20250333521 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-10-30 [patent_title] => IL10RB BINDING MOLECULES AND ENCODING NUCLEIC ACIDS [patent_app_type] => utility [patent_app_number] => 19/095314 [patent_app_country] => US [patent_app_date] => 2025-03-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32498 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19095314 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20321433 [patent_doc_number] => 20250333521 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-10-30 [patent_title] => IL10RB BINDING MOLECULES AND ENCODING NUCLEIC ACIDS [patent_app_type] => utility [patent_app_number] => 19/095314 [patent_app_country] => US [patent_app_date] => 2025-03-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32498 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19095314 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20067110 [patent_doc_number] => 20250205332 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-06-26 [patent_title] => METHODS OF TREATING PSORIATIC ARTHRITIS USING IL-17 ANTAGONISTS [patent_app_type] => utility [patent_app_number] => 19/061831 [patent_app_country] => US [patent_app_date] => 2025-02-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34652 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19061831 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20023223 [patent_doc_number] => 20250161445 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-05-22 [patent_title] => METHODS OF TREATING PSORIASIS USING IL-17 ANTAGONISTS [patent_app_type] => utility [patent_app_number] => 18/983037 [patent_app_country] => US [patent_app_date] => 2024-12-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24652 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18983037 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20023221 [patent_doc_number] => 20250161443 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-05-22 [patent_title] => METHODS OF ADMINISTERING SECUKINUMAB [patent_app_type] => utility [patent_app_number] => 18/983030 [patent_app_country] => US [patent_app_date] => 2024-12-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24618 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18983030 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20023221 [patent_doc_number] => 20250161443 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-05-22 [patent_title] => METHODS OF ADMINISTERING SECUKINUMAB [patent_app_type] => utility [patent_app_number] => 18/983030 [patent_app_country] => US [patent_app_date] => 2024-12-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24618 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18983030 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20023222 [patent_doc_number] => 20250161444 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-05-22 [patent_title] => METHODS OF TREATING PSORIASIS USING IL-17 ANTAGONISTS [patent_app_type] => utility [patent_app_number] => 18/983034 [patent_app_country] => US [patent_app_date] => 2024-12-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24616 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18983034 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19754423 [patent_doc_number] => 20250042988 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-02-06 [patent_title] => METHODS OF ACHIEVING SAFE AND SUSTAINED CONTROL OF IL-17-DEPENDENT CONDITIONS IN SUBJECTS RESPONSIVE TO TREATMENT WITH AN ANTI-IL 17A/F NANOBODY [patent_app_type] => utility [patent_app_number] => 18/921679 [patent_app_country] => US [patent_app_date] => 2024-10-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10879 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18921679 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19754423 [patent_doc_number] => 20250042988 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-02-06 [patent_title] => METHODS OF ACHIEVING SAFE AND SUSTAINED CONTROL OF IL-17-DEPENDENT CONDITIONS IN SUBJECTS RESPONSIVE TO TREATMENT WITH AN ANTI-IL 17A/F NANOBODY [patent_app_type] => utility [patent_app_number] => 18/921679 [patent_app_country] => US [patent_app_date] => 2024-10-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10879 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18921679 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19745676 [patent_doc_number] => 20250034241 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-30 [patent_title] => SELECTIVE REDUCTION OF CYSTEINE RESIDUES IN IL-17 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 18/800977 [patent_app_country] => US [patent_app_date] => 2024-08-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37199 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 76 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18800977 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19528180 [patent_doc_number] => 20240352082 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-24 [patent_title] => ORTHOGONAL IL-21 RECEPTOR/CYTOKINE SYSTEMS [patent_app_type] => utility [patent_app_number] => 18/733339 [patent_app_country] => US [patent_app_date] => 2024-06-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15785 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18733339 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19601113 [patent_doc_number] => 20240391993 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-28 [patent_title] => METHODS AND COMPOSITIONS FOR TREATING PLAQUE PSORIASIS [patent_app_type] => utility [patent_app_number] => 18/674352 [patent_app_country] => US [patent_app_date] => 2024-05-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 80575 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18674352 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19528253 [patent_doc_number] => 20240352155 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-24 [patent_title] => COVALENT MULTI-SPECIFIC ANTIBODY [patent_app_type] => utility [patent_app_number] => 18/668012 [patent_app_country] => US [patent_app_date] => 2024-05-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6180 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 71 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18668012 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19586420 [patent_doc_number] => 20240383977 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-21 [patent_title] => ANTI-GIANT PANDA LIF MONOCLONAL ANTIBODY, HYBRIDOMA CELL LINE, AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/610618 [patent_app_country] => US [patent_app_date] => 2024-03-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5685 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18610618 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19380936 [patent_doc_number] => 20240270806 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-15 [patent_title] => PROTEASE-ACTIVATED CYTOKINE [patent_app_type] => utility [patent_app_number] => 18/414813 [patent_app_country] => US [patent_app_date] => 2024-01-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 142112 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18414813 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19380936 [patent_doc_number] => 20240270806 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-15 [patent_title] => PROTEASE-ACTIVATED CYTOKINE [patent_app_type] => utility [patent_app_number] => 18/414813 [patent_app_country] => US [patent_app_date] => 2024-01-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 142112 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18414813 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19318341 [patent_doc_number] => 20240239884 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-18 [patent_title] => SOLUTION FORMULATIONS OF ENGINEERED ANTI-IL-23p19 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 18/405772 [patent_app_country] => US [patent_app_date] => 2024-01-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12244 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18405772 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19142184 [patent_doc_number] => 20240141008 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-02 [patent_title] => THERAPEUTICALLY ACTIVE ALDESLEUKIN HIGHLY STABLE IN LIQUID PHARMACEUTICAL COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 18/519193 [patent_app_country] => US [patent_app_date] => 2023-11-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27253 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18519193 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19142184 [patent_doc_number] => 20240141008 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-02 [patent_title] => THERAPEUTICALLY ACTIVE ALDESLEUKIN HIGHLY STABLE IN LIQUID PHARMACEUTICAL COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 18/519193 [patent_app_country] => US [patent_app_date] => 2023-11-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27253 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18519193 [rel_patent_id] =>[rel_patent_doc_number] =>)